A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Aspart to NovoRapid® Penfill® in Healthy Subjects


Pharmacokinetics and pharmacodynamics study of 2 formulations of insulin aspart (Insulin Aspart GEROPHARM vers. NovoRapid® Penfill® Novo Nordisk)

Full Title of Study: “A Randomized Double Blinded Two-way Crossover Single-dose Pharmacokinetics and Pharmacodynamics Study of Insulin Aspart (LLC “GEROPHARM”, Russia) Versus NovoRapid® Penfill® (Novo Nordisk) in Healthy Subjects Using the Euglycemic Clamp Technique”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Basic Science
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: December 19, 2018

Detailed Description

A randomized double blinded two-way crossover single-dose pharmacokinetics and pharmacodynamics study of Insulin Aspart (LLC "GEROPHARM", Russia) versus NovoRapid® Penfill® (Novo Nordisk) in normal healthy subjects using the euglycemic clamp technique


  • Drug: Insulin Aspart
    • insulin aspart in doses 0.3 IU/kg
  • Drug: NovoRapid® Penfill®
    • insulin aspart in doses 0.3 IU/kg

Arms, Groups and Cohorts

  • Experimental: Insulin Aspart
    • Single subcutaneous administration of Insulin Aspart in dose 0.3 IU / kg
  • Active Comparator: NovoRapid® Penfill®
    • Single subcutaneous administration of NovoRapid® Penfill® in dose 0.3 IU / kg

Clinical Trial Outcome Measures

Primary Measures

  • AUC(0-t)
    • Time Frame: -60, -30, 0 minutes (pre-dose) and 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 135, 150, 165, 240, 300, 360, 420 and 480 minutes post-dose
    • Pharmacokinetics of insulin aspart by Assessment of Area Under the Curve From Time Zero Extrapolated to “t” (AUC(0-t))
  • Cmax
    • Time Frame: -60, -30, 0 minutes (pre-dose) and 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 135, 150, 165, 240, 300, 360, 420 and 480 minutes post-dose
    • Pharmacokinetics of insulin aspart by Assessment of Observed Maximum Plasma Concentration (Cmax)

Participating in This Clinical Trial

Inclusion Criteria

1. Signed informed consent.

2. Caucasian males having a confirmed healthy diagnosis as per data of standard clinical, laboratory, and instrumental examination methods.

3. Age of 18-45 (both incl.).

4. Body mass index equal to 18.5-30.0 kg/m2, body weight equal to 55.0-100.0 kg (both incl.).

5. Volunteers' consent to all restrictions imposed during the study, including adequate methods of contraception.

6. Russian citizenship.

Exclusion Criteria

1. Weighed allergic anamnesis.

2. Increased sensitivity in the history of heparin, insulin or any of the excipients of the study drugs.

3. Any acute and chronic diseases, incl.:

1. of the cardiovascular system, bronchopulmonary, neuroendocrine systems, as well as diseases of the gastrointestinal tract, liver, kidneys, blood.

2. positive tests: hepatitis B (Ag), hepatitis C (Ab), HIV (Ab), syphilis (Ab).

4. 10% deviation from references in lab tests.

5. Abnormalities of the ECG and deviations in basic vital signs from the norms (screening).

6. Episodes of hypoglycemia in the anamnesis; the presence in the family history of cases of a verified diagnosis of diabetes mellitus in the immediate family.

7. Fasting plasma glucose> 6.1 mmol / L.

8. HbA1C> 6% (screening).

9. Oral glucose tolerance test – blood glucose level ≥ 7.8 mmol / l (2 hours after loading with glucose).

10. Deep vein thrombosis of lower extremities in a history of life or in a family history.

11. Any diet (vegetarian, etc.) extreme physical exercise, night shift work.

12. Taking medications, phytopreparations, biologically active supplements less than 14 days before screening.

13. History of significant drugs abuse conditions for 3 years prior to screening.

14. Significant blood loss less than 3 months before the screening.

15. Recovery after surgery process; scheduled surgery.

16. Mental, physical and other reasons that do not allow to adequately assess their behavior and properly fulfill the conditions of the research protocol, including psychiatric disorders.

17. A positive test for the content of drugs in the urine (screening)

18. Receiving more than 10 units. alcohol per week (1 unit of alcohol is equivalent to 0.5 liters of beer, 200 ml of wine or 50 ml of strong alcohol) or anamnestic information about alcoholism.

19. Positive test for alcohol content in the exhaled air.

20. Nicotine dependence (use of tobacco less than 6 months before the start of screening).

21. Presence of oncology disease in the anamnesis 5 years prior the start of screening.

22. Participation in a clinical trial of any medications less than 3 months or 5 half-lives before the IP administration.

23. Any conditions that make it difficult, according to the informed opinion of the investigating physician, that volunteer participation in studies.

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Geropharm
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.